Elite Pharmaceuticals, Inc. (ELTP) Operating cash flow 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$23.7MFY2026 · since FY2017: -$7.9M → $23.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $23.7M | +218.5% |
| FY2025 | $7.5M | +330.5% |
| FY2024 | -$3.2M | -196.9% |
| FY2023 | $3.3M | -48.7% |
| FY2022 | $6.5M | +103.8% |
| FY2021 | $3.2M | +278.0% |
| FY2020 | -$1.8M | +73.6% |
| FY2019 | -$6.8M | -41.2% |
| FY2018 | -$4.8M | +39.0% |
| FY2017 | -$7.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTP financial trends
ELTP RevenueELTP Net incomeELTP Net marginELTP Gross profitELTP Gross marginELTP Operating incomeELTP Operating marginELTP Free cash flowELTP Capital expendituresELTP Return on equityELTP Stock buybacksELTP Dividends paidELTP Total assetsELTP Total liabilitiesELTP Shareholders’ equityELTP overview →